Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.48 |
| ▸ | PRKDC | P78527 | 7/20 | 0.48 |
| ▸ | SRC | P12931 | 6/20 | 0.48 |
| ▸ | ABL1 | P00519 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | HCK | P08631 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12808147 | 0.92 | BTK (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL30387175 | 0.87 | PIK3CD (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL20748491 | 0.86 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL5065122 | 0.84 | PIK3CD (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL15613778 | 0.84 | PIK3CD (0.42) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL3782102 | 0.84 | PIK3CD (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL3715031 | 0.84 | SRC (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL408618 | 0.83 | PIK3CD (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL23917208 | 0.83 | MAP2K4 (0.48) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL21467053 | 0.83 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| CN-102712645-A | Compound (I) | RESPIVERT LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3CA 3148/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3CA 3148/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CG 8/4885PIK3CD 2/4885PIK3CA 6/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3CA 3148/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CG 126/4885PIK3CD 103/4885PIK3CA 144/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3CA 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.